NEW YORK, March 15, 2018 -- The Law Offices of Vincent Wong announce that class action lawsuits have been commenced in the United States District Court for the Eastern District of New York on behalf of investors who purchased Synergy Pharmaceuticals Inc. ("Synergy") (NASDAQ:SGYP) securities between November 10, 2016 and November 14, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-c/synergy-pharmaceuticals-inc?wire=3. There is no cost or obligation to you.
According to the complaints, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) the loan from CRG Partners III L.P. (“CRG Loan”) did not fund Synergy’s operations through 2019; (2) the Company could not access the second tranche of $100 million financing on or before February 28, 2018 without issuing dilutive equity; and (3) the Company could not access the third tranche of the CRG Loan if and when needed because terms were required to be met in order to access those tranches. On September 5, 2017, Synergy issued a press release announcing it had closed on a “non-dilutive” $300 million loan from CRG Partners III L.P., which would be available to Synergy “when needed” and fund the Company’s operations through 2019. On November 14, 2017, Synergy revealed that terms of the loan agreement, omitted from prior statements regarding the loan, prevented it from accessing $200 million of the loan without conducting a dilutive secondary offering or offerings of shares to raise cash and, as such, the Company was conducting a secondary offering of its shares.
If you suffered a loss in Synergy you have until April 10, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/synergy-pharmaceuticals-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]


Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada
CATL Shares Fall as Hungary Plant Faces Safety Halt
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks
CIA-Linked Investor Helped Quantum Systems Expand in US
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall
France Targets Shein, Temu With Fast-Fashion Fees
Trump Secures Drug Pricing Deals With Nine Pharma Companies
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses
Shein Shares Slide 9% in Hong Kong IPO Debut
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up
OpenAI Nears Astra AI Model Launch With Safety Focus
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 



